# Ipilimumab + Temozolomide in Metastatic Melanoma

> **NCT01119508** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 64 (actual)

## Conditions studied

- Metastatic Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01119508
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01119508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01119508, "Ipilimumab + Temozolomide in Metastatic Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01119508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*